LFLisa Feldman

Lisa Feldman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisa Feldman has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Behnam Badie

    Division of Neurosurgery, City of Hope National Medical Center, Duarte, USA

    2 shared publications
  • Christine Brown

    Departments of Cancer Immunotherapy & Tumor Immunology and Hematology & Hematopoietic Call Transplantation, City of Hope National Medical Center, Duarte, USA

    2 shared publications
  • Yujun Wang

    Division of Neurosurgery, Department of Surgery, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA

    2 shared publications
  • Babak Kateb

    Society for Brain Mapping and Therapeutics

    1 shared publication
  • Baishali Chaudhuri

    Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer (CSI-Cancer), University of Southern California, Los Angeles, CA 90089, USA

    1 shared publication
  • Barbara Fackelmeier

    Centre for Brain Research, University of Auckland , Auckland, New Zealand

    1 shared publication

Latest Publications

  • Open Access

    Microenvironmental IL13 Rα2 Expression and Enable Extracellular Vesicle-Mediated Antigen Transfer in Glioblastoma

    by Yujun Wang, Ryan Urak, Clara Chen, Martha Salas, Christine Brown, Lisa Anne Feldman

    Background/Objectives: Interleukin-13 receptor alpha 2 (IL13Rα2), expressed in more than 75% of glioblastomas (GBM), is a promising chimeric antigen receptor (CAR) T cell target. We investigated how microenvironmental stresses regulate IL13Rα2 expression and whether extracellular vesicle (EV)-mediated antigen transfer modulates CAR T cell killing. Methods: Patient-derived brain tumor and other GBM cell lines were exposed to hypoxia, desferrioxamine (DFO), or reduced fetal bovine serum (FBS). Western blotting assessed IL13Rα2 expression and recovery following reoxygenation. Fluorescence imaging evaluated EV interactions with recipient cells, and cytotoxicity assays assessed CAR T cell killing. Results: Hypoxia and DFO markedly suppressed IL13Rα2 expression. Exposure to 1% oxygen for 48 h reduced protein levels by 40–70%; expression recovered to near-baseline levels within 48 h of reoxygenation. Reduced FBS concentrations for 48 h also decreased IL13Rα2 expression compared with 10% FBS. Findings suggested potential contributions from ubiquitin-dependent degradation and transcriptional mechanisms. IL13Rα2-expressing EVs showed a slight increase under hypoxia. Fluorescence imaging confirmed that IL13Rα2-containing EVs attached to or entered recipient GBM cells within hours. EV-mediated antigen transfer increased CAR T cell killing by 3–5%. Conclusions: Hypoxia and nutrient availability dynamically regulate IL13Rα2 expression, while EVs can transfer the antigen between GBM cells and modestly enhance CAR T cell killing. These findings highlight reversible antigen modulation and EV-mediated antigen redistribution as mechanisms that could inform strategies to overcome antigen escape and improve immune targeting in GBM.

  • Open Access

    The Landscape of Tumor Dissemination in Leptomeningeal Disease: Mapping CTC Plasticity and Regional Heterogeneity Across Blood and CSF Compartments

    by Stephanie N. Shishido, Baishali Chaudhuri, Vidur Mushran, Kena Ihle, Yujun Wang, Colt A. Egelston, James Hicks, Lisa Feldman, Eliza Barragan, Peter Kuhn

    Background/Objectives: Leptomeningeal disease (LMD) is among the most severe complications of metastatic breast cancer, with median survival measured in weeks. Definitive diagnosis relies on neuroimaging and cerebrospinal fluid (CSF) cytology, which carries a false-negative rate of 40–50% at a single lumbar puncture. Improved tools for detecting and characterizing tumor cells across systemic and central nervous system (CNS) compartments are urgently needed. Methods: We applied an enrichment-free, fluorescence whole-slide imaging (fWSI)-based liquid biopsy platform to ante-mortem and post-mortem peripheral blood (PB) and CSF from five patients with metastatic breast cancer and confirmed or suspected LMD, collected through the City of Hope LEGACY warm autopsy program. Circulating tumor cells (CTCs) were classified by immunophenotype (cytokeratin [CK], vimentin [VIM], CD45/CD31) and morphology. Select cells underwent single-cell copy number variation (CNV) profiling by low-pass whole-genome sequencing. Results: Across 23 samples (11 PB, 12 CSF), we identified marked compartmental heterogeneity in CTC burden, phenotype, and genomic architecture. In the one patient (Patient 1) sampled across all four ventricular-to-cisternal CSF sites, CTC frequency declined from proximal to distal compartments (11.4% in the right lateral ventricle to 0.6% at the foramen magnum), a single-patient observation consistent with a proximal-to-distal gradient. Patients with active, untreated LMD showed high CSF CTC incidence with both epithelial and mesenchymal phenotypes, whereas the two patients receiving intrathecal therapy each showed low or absent CSF CTCs; given the small numbers involved and a plausible technical confound in a third patient, we interpret this association cautiously. Single-cell CNV profiling of CSF-derived CTCs across patients with active LMD revealed highly concordant chromosomal aberration profiles, 100% of CK+ CSF CTCs analyzed carried chromosomal aberrations, consistent with, though not formally establishing, expansion of a genomically evolved subclone within the leptomeningeal compartment; PB-derived cells showed substantially greater heterogeneity. In the two patients with paired post-mortem arterial and venous PB, arterial blood showed higher total rare cell counts in both, and higher CK-positive CTC incidence in one (1425.73 vs. undetectable epi.CTC/mL); the other showed the reverse for this specific metric. Conclusions: Enrichment-free, multi-compartment liquid biopsy reveals a regionally heterogeneous and biologically structured landscape in breast cancer LMD not resolvable by conventional cytology or single-site venous sampling. These findings are consistent with a hypothesis-generating model in which the leptomeningeal space acts as a selective niche for clonally convergent tumor expansion. They also point to the potential of regionally resolved CTC profiling for monitoring LMD treatment response in future, larger cohorts.

  • Open Access

    CBX6 and CA9 as predictive indicators and therapeutic targets in GBM

    by Yujun Wang, Yongsheng Jia, Yate-Ching Yuan, Gang Li, Jinhui Wang, Mike Yue Chen, Lisa Anne Feldman


  • Intralesional and Intraparenchymal Convection-Enhanced Delivery of Nanoparticles

    by Clara Chen, Cynthia Basulto, Talha Nazir, Namath Hussain, Babak Kateb, Mike Y. Chen, Kai-Uwe Lewandrowski, Lisa Feldman


  • Top Cited Papers
    Open Access

    Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments

    by Lisa Feldman

    Glioblastoma (GBM) tumors are the most aggressive primary brain tumors in adults that, despite maximum treatment, carry a dismal prognosis. GBM tumors exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells and creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring the proliferation of immunosuppressive cells and inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, and CAR-T cell therapy, represent promising avenues for GBM treatment. However, challenges such as tumor heterogeneity, immunosuppressive TME, and BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, including combination therapies and targeting hypoxia, are actively being explored to improve outcomes for GBM patients. Targeting hypoxia in combination with immunotherapy represents a potential strategy to enhance treatment efficacy.


  • Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma

    by Lisa Feldman, Christine Brown, Behnam Badie

    Glioblastoma (GBM) are the most common and aggressive primary brain tumors in adults. Current mainstay treatments include surgery, chemotherapy, and radiation; however, these are ineffective. As a result, immunotherapy treatment strategies are being developed to harness the body’s natural defense mechanisms against gliomas. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells uses patients’ own T cells that are genetically modified to target tumor-associated antigens. These cells are harvested from patients, engineered to target specific proteins expressed by the tumor and re-injected into the patient with the goal of destroying tumor cells. In this mini review, we outline the history of CAR T cell therapy, describe current antigen targets, and review challenges this treatment faces specifically in targeting GBM.


  • Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment

    by Lisa Feldman, Christine Brown, Behnam Badie

    Glioblastoma multiforme (GBM) are the most common and among the deadliest brain tumors in adults. Current mainstay treatments are insufficient to treat this tumor, and therefore, more effective therapies are desperately needed. Immunotherapy, which takes advantage of the body's natural defense mechanism, is an exciting emerging field in neuro-oncology. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells provides a treatment strategy based on using patients’ own selected and genetically engineered cells that target tumor-associated antigens. These cells are harvested from patients, modified to target specific proteins expressed by the tumor, and re-introduced into the patient with the goal of destroying tumor cells. Here, we review the history of CAR T-cell therapy, and describe the characteristics of various generations of CAR T therapies, and the challenges inherent to treatment of GBM. Finally, we describe recent and current CAR T clinical trials designed to combat GBM.


  • Open Access

    Connexin43 Expression and Associated Chronic Inflammation Presages the Development of Cerebral Radiation Necrosis

    by Lisa A Feldman, Shewta Haldankar, Simon J O’cArroll, Karen Liu, Barbara Fackelmeier, William C Broaddus, Tony Anene-Maidoh, Colin R Green, Joel R Garbow, Jian Guan

    Cerebral radiation necrosis (CRN) is a delayed complication of radiosurgery that can result in severe neurological deficits. The biological changes leading to necrotic damage may identify therapeutic targets for this complication. Connexin43 expression associated with chronic inflammation may presage the development of CRN. A mouse model of delayed CRN was used. The left hemispheres of adult female mice were irradiated with single-fraction, high-dose radiation using a Leksell Gamma Knife. The brains were collected 1 and 4 days, and 1–3 weeks after the radiation. The expression of connexin43, interleukin-1β (IL-1β), GFAP, isolectin B-4, and fibrinogen was evaluated using immunohistochemical staining and image analysis. Compared with the baseline, the area of connexin43 and IL-1β staining was increased in ipsilateral hemispheres 4 days after radiation. Over the following 3 weeks, the density of connexin43 gradually increased in parallel with progressive increases in GFAP, isolectin B-4, and fibrinogen labeling. The overexpression of connexin43 in parallel with IL-1β spread into the affected brain regions first. Further intensified upregulation of connexin43 was associated with escalated astrocytosis, microgliosis, and blood-brain barrier breach. Connexin43-mediated inflammation may underlie radiation necrosis and further investigation of connexin43 hemichannel blockage is merited for the treatment of CRN.